OTCMKTS:SPHDF - Santhera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.07
▼ -0.22 (-6.69%)
1 month | 3 months | 12 months
Get New Santhera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPHDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPHDF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Santhera Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.07.
Hold
The current consensus among 2 contributing investment analysts is to hold stock in Santhera Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/6/2020Credit Suisse GroupReiterated RatingNeutral
i
10/6/2020CSFBUpgradeUnderperform ➝ Neutral
i
10/6/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral
i
(Data available from 11/27/2015 forward)
Santhera Pharmaceuticals logo
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidates include Puldysa (idebenone) and vamorolone, which are being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It had collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.
Read More

Today's Range

Now: $3.07
$3.07
$3.08

50 Day Range

MA: $3.59
$3.07
$4.90

52 Week Range

Now: $3.07
$3.07
$12.40

Volume

1,000 shs

Average Volume

6,486 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A